

Microwave Assisted Neat Synthesis Of α -Aminophosphonate / Phosphinate Derivatives Of 2-(2-Aminophenyl)Benzothiazole As Potent Antimicrobial And Antioxidant Agents

Shaik Thaslim Basha, Hasti Sudhamani, Syed Rasheed, Nagam Venkateswarlu, Tartte Vijaya & Chamarthi Naga Raju

To cite this article: Shaik Thaslim Basha, Hasti Sudhamani, Syed Rasheed, Nagam Venkateswarlu, Tartte Vijaya & Chamarthi Naga Raju (2016): Microwave Assisted Neat Synthesis Of α -Aminophosphonate / Phosphinate Derivatives Of 2-(2-Aminophenyl)Benzothiazole As Potent Antimicrobial And Antioxidant Agents, Phosphorus, Sulfur, and Silicon and the Related Elements, DOI: [10.1080/10426507.2016.1192629](https://doi.org/10.1080/10426507.2016.1192629)

To link to this article: <http://dx.doi.org/10.1080/10426507.2016.1192629>



Accepted author version posted online: 31 May 2016.
Published online: 31 May 2016.



Submit your article to this journal [↗](#)



Article views: 3



View related articles [↗](#)



View Crossmark data [↗](#)

Benzothiazole derivatives as potent biological agents

MICROWAVE ASSISTED NEAT SYNTHESIS OF α -

AMINOPHOSPHONATE/PHOSPHINATE DERIVATIVES OF 2-(2-

AMINOPHENYL)BENZOTHAZOLE AS POTENT ANTIMICROBIAL AND

ANTIOXIDANT AGENTS

Shaik Thaslim Basha¹, Hasti Sudhamani¹, Syed Rasheed¹, Nagam Venkateswarlu², Tartte

Vijaya² and Chamarthi Naga Raju^{1,*}


¹Department of Chemistry, Sri Venkateswara University, Tirupati-517502, Andhra Pradesh, India.

²Department of Botany, Sri Venkateswara University, Tirupati-517502, Andhra Pradesh, India.

*Corresponding author: email: rajuchamarthi10@gmail.com

Abstract

A series diethyl/ethylphenyl(2-(benzo[*d*]thiazol-2-yl)phenylamino)phosphonates and phosphinates were synthesized under microwave irradiation and neat conditions *via* Kabachnik-Fields reaction in high yields (80-93%). The compounds were screened for antimicrobial and antioxidant properties. A few compounds showed effective antibacterial and antifungal agents at MIC value 12.5 $\mu\text{g/mL}$ as compared with the standard at MIC value 6.25 $\mu\text{g/mL}$.



Keywords

2-(2-Aminophenyl) benzothiazole, Neat conditions, Microwave irradiation, Kabachnik-Field reaction, Antimicrobial and Antioxidant activity.

INTRODUCTION

Organic chemists now focus to develop new transformations that are not only efficient, selective and high yielding but are also environmentally benign. Microwave assisted organic syntheses have gained enormous attention of the chemists due to their advantages such as shorter reaction times, cleaner products, operational simplicity, higher yields and being a potential alternative to accomplish the effective synthesis of heterocyclic bioactive compounds.¹ Meanwhile, neat reactions or green chemical approaches have attained great advantages in chemical processes by reducing environmental pollution.²

Heterocycles are versatile building blocks in design and discovery of new physiological/pharmacologically active compounds. The benzothiazole scaffold represents an important moiety found in numerous drugs and agrochemicals.³ Benzothiazole derivatives have a wide range of biological applications such as anticancer,⁴ antimalarial,⁵ antiviral,⁶ anti-inflammatory,⁷ antidiabetic,⁸ antihelminthic,⁹ antimicrobial,¹⁰ antioxidant,¹¹ and Alzheimer's disease.¹² Benzothiazole also exhibits industrial applications such as vulcanization,¹³ dyes, nonlinear optics (NLO)¹⁴ and radioactive amyloid imaging agents.

On the other hand, α -aminophosphonates show broad and biologically diverse applications due to their structural resemblance of the naturally occurring α -amino acids.¹⁵ Thus, α -aminophosphonates occupy a distinctive position in the design and discovery of new drug moieties for the treatment of various ailments. Their use as herbicides, antitumor agents, enzyme inhibitors, haptens of catalytic antibodies, inhibitors of UDP-galactopyranose mutase, inhibitors of serine hydrolases and pharmacogenic agents.¹⁶⁻²³

Based on the wide variety of biological applications of benzothiazoles and α -aminophosphonates, herein, we report the synthesis of hybrid compounds containing these two pharmacophoric units in a single entity by using simple, neat, and catalyst-free, more convenient and eco-friendly approach under microwave condition. Further, these compounds were screened for anti-bacterial, anti-fungal activity and also for free radicals scavenging.

RESULTS AND DISCUSSION

In continuation of our research in the development of new biologically active α -aminophosphonates and their biological applications,^{17, 23, 24} α -aminophosphonate and phosphinate derivatives of 2-(2-aminophenyl)benzothiazole were synthesized in solvent-free conditions, under microwave irradiation *via* Kabachnik-Fields reaction.²⁵⁻²⁷ We started the synthesis by cyclo-condensation of 2-aminothiophenol (**3**) with 2-aminobenzaldehyde (**4**) in the presence of glacial acetic acid under microwave irradiation to obtain,²⁸ 2-(2-aminophenyl)benzothiazole as depicted in **Scheme 1**.

To synthesize an α -aminophosphonate library of benzothiazoles, we reinvestigated the reaction conditions by selecting 2-(2-aminophenyl)benzothiazole (**5**), 2,4-dichlorobenzaldehyde (**7a**) and diethyl phosphite (**8**) as model substrates under microwave conditions **Scheme 2**. Initially the model reaction was carried out without catalyst and solvent at 490 W (**Table S1, Entry 1**). The reaction was completed in 10 min with high yield (90%). The progress of the reaction was also tested in different solvents and solvent-free with different Lewis acid catalysts such as AlCl₃, FeCl₃, CuI, ZnCl₂, ZnBr₂, BiCl₃, NbCl₅ and ZnO (**Table S1, Entry 2-15**). As

previously reported advantages of silica supported catalysts, they were used to get high yields (87, 90 and 92%).²⁴No significant difference in the yield was observed when the reaction was carried out with catalyst as well as undersolvent-free conditions (90%) **Table S1**.

The model reaction was optimized by screening at 700, 560, 455, 420 and 350 Watts to find out the effect of microwave power on the reaction. A microwave power 455 W was found to be optimal(**Figure 1**). The generality of the reaction conditions was tested with different aromatic and heterocyclic aldehydes **6a-f**, diethyl phosphite (**7**) and ethyl phenylphosphinate (**8**) as depicted in **Scheme 3**.

Spectroscopy

The structure of the novel title compounds **9-20** was confirmed by FT-IR, ¹H, ¹³C carbon, ³¹P NMR, mass spectra and elemental analysis. The ¹H NMR spectroscopic signals observed δ 1.36-1.08 (triplet/multiplet) and δ 4.32-3.81 (multiplet) confirms the presence of the O-CH₂-CH₃ phosphate functionality. The signals at δ 5.48-4.88 ppm (doublet/doublet of doublet) correspond to P-CH. NH appeared as singlet/multiplet at δ 10.43-10.08 ppm.²⁹ In the ¹³C NMR spectra, the chemical shift at δ 16.7-16.2 (doublet, $J = 6.4$ - 5.4 Hz), δ 56.4-52.0 (doublet, $J = 155.5$ - 134.0 Hz), and 64.2-62.3 ppm (doublet, $J = 7.5$ - 6.2 Hz), corresponds to the O-CH₂-CH₃, P-CH and O-CH₂ groups, respectively. In the ³¹P NMR spectra, the signals at δ 20.9-19.6 and 36.4-35.2 ppm are due to the phosphorus atom of phosphonates **9-14** and phosphinates **15-20**, respectively.²⁴ The FT-IR spectra showed absorption bands at 3300-3109 cm⁻¹ for NH str, 1230-1205 cm⁻¹ for P=O str, and 1029-1005 cm⁻¹ for P-O str of the α -aminophosphonates and phosphinates. The structures of the compounds were further supported by molecular ion peaks in the mass spectra, and elemental analytical data.

Biological activity**Antimicrobial activity**

The α -aminophosphonates and phosphinates were screened for their *in vitro* antibacterial activity against four bacterial stains, *Bacillus subtilis*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Escherichiacoliby* use of the agar well diffusion method.³⁰ Minimum inhibitory concentrations (MIC) weredetermined by themicrotiter dilution assay.³¹ All title compounds showed promising activity against the bacterial pathogens at 100 $\mu\text{g}/\text{mL}$ concentration and most of the compounds exhibited an increased inhibition activity compared with the starting compound 2-(2-aminophenyl)benzothiazole (**3**) (Table S 2). Compounds **18**, **19** and **20** showed the highest inhibition activity with lowest MIC values 12.5 $\mu\text{g}/\text{mL}$ against all bacterial stains. The reason might be the presence of the heterocyclic moiety. Compound **11>16>12>13** showed moderate inhibition activity against *Bacillus subtilis*, **16>13>12>11** showed better activity against *Staphylococcus aureus*. Similarly, **11>13>16** showed moderate activity against *Pseudomonas aeruginosa* and **13>11** showed reasonable activity against *Escherichiacoli*.

The new compounds **9-20** were screened for *in vitro* antifungal activity against four fungal pathogens *Candida albicans*, *Candida non-albicans*, *Aspergillus niger* and *Penicillium chrysogenum* by use of the disc diffusion method³² and the microtiter dilution assay for MIC.³¹ Among the compounds, **20>19>18** exhibited good inhibition activity at 100 $\mu\text{g}/\text{mL}$ and with lowest MIC values 12.5 $\mu\text{g}/\text{mL}$ against fungal pathogens. Moderate inhibition activity of compounds was observed in the order **11>13>14>9** against *Candida albicans*, **11>16>13** against *Candida non-albicans*, **11>13>14** against *Aspergillus niger* and **11>13>14>12** against *Penicillium chrysogenum* as shown in Table S 2 (Supplemental Materials).

Antioxidant activity

The antioxidant activity of the synthesized compounds was evaluated by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical assay³³ (Table S 3) and hydrogen peroxide scavenging activity³⁴ (Table S 4) at four concentrations (25, 50, 75 and 100 µg/mL). IC₅₀ values were also calculated from these methods. It was notified from the antioxidant data that compounds **20**>**18**>**19** showed good radical scavenging activity, probably due to the presence of the heterocyclic ring in the phosphinates, involved rapid abstraction of free radicals. Compounds, **20**(IC₅₀, 32.09, 51.42 µg/mL) and **18**(IC₅₀, 41.11, 61.94 µg/mL) exhibited an IC₅₀ value closer to the standard antioxidant, ascorbic acid (IC₅₀, 26.5, 41.76 µg/mL) as shown in Figure 2.

A noteworthy enhancement of the antimicrobial and antioxidant activities was observed for all compounds substituted with heterocyclic ring in ethyl phenyl [2-(benzo[*d*]thiazol-2-yl)phenylamino]methylphosphinates **18** and **20** when compared with diethyl [2-(benzo[*d*]thiazol-2-yl)phenylamino]methylphosphonates **12** and **13**.

CONCLUSION

Keeping in mind the hazardous impact on human kind, catalyst and solvent-free conditions have been exploited to synthesize diethyl and ethyl phenyl [2-(benzo[*d*]thiazol-2-yl)phenylamino] substituted methylphosphonates/phosphinates **9-20** in high yields under microwave irradiation in short reaction time. The product compounds were screened for their antibacterial, antifungal and antioxidant activities. The biological assay results revealed that the compounds possessing a heterocyclic ring substitution showed an increased inhibition activity at lower concentration than the substituted aromatic compounds. Among the heterocyclic

compounds, **18**, **19** and **20** showed the highest activity which drew our interest to further evaluating these potent compounds *in vivo*.

EXPERIMENTAL

General methods

All solvents and chemicals were purchased from Merck and Sigma Aldrich, respectively and were used without further purification. Melting points were determined in open capillary tube on a Guna melting pointing apparatus and are uncorrected. Microwave irradiation was carried out by use of a CATA-4R microwave oven. IR spectra were recorded on a Bruker ALPHA interferometer instrument. ^1H , ^{13}C and ^{31}P NMR spectra were recorded on a Bruker 500 MHz instrument. CDCl_3 and TMS were used as solvents and internal reference for ^1H and ^{13}C NMR. Chemical shifts δ and coupling constants J were expressed in ppm and Hz, respectively. MS were recorded on ESI-MS in positive mode. Elemental analysis were carried out in FLASH EA Thermo Finnigan 1112 instrument. The Supplemental Materials contains sample ^1H , ^{13}C , ^{31}P NMR and mass spectra for 11 (Figures S 1 -- S 4)

2-(2-Aminophenyl)benzothiazole (5):²⁸ A mixture of 2-aminothiophenol **3** (750 mg, 6 mmol), 2-aminobenzaldehyde **4** (720 mg, 6 mmol) and 2 mL of glacial acetic acid were taken in a 100 mL flat bottomed flask. The reaction mixture was irradiated with microwave radiation at 490 W. The progress of the reaction was monitored at 1 min intervals by use of TLC (hexane/EtOAc 7:3). After completion, the reaction mixture was washed with water and extracted with CH_2Cl_2 . The organic layer was dried over anhydrous Na_2SO_4 and concentrated in vacuum to get a yellowish green solid. To obtain pure **5**, column chromatography was performed (hexane/EtOAc 4:1).

Diethyl [2-(benzo[*d*]thiazol-2-yl)phenylamino]-(2,4-dichlorophenyl)methane-phosphonate (9): **5** (220 mg, 1 mmol), 2,4-dichlorobenzaldehyde **6a** (170 mg, 1 mmol) and diethyl phosphite **7** (1.5 mmol) were taken in a flat bottomed flask. The mixture was microwave irradiated at 455 W under neat conditions. The progress of the reaction was monitored by TLC (hexane/EtOAc 2:3) in 1 min intervals. After completion of the reaction, the reaction mixture was washed with water and extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄ and extracted with EtOAc. The solvents were removed under reduced pressure. Pure **9** was obtained by column chromatography (hexane/EtOAc 3:1) as pale yellow solid, m. p.: 83-85°C. IR (ν_{\max} , cm⁻¹): 3226 (NH), 1249 (P=O), 1016 (P-O-C). ¹H NMR (400 MHz) δ : 10.43 (1H, s, NH), 8.12 (1H, d, *J* = 8.0 Hz, Ar-H), 7.90 (1H, d, *J* = 8.0 Hz, Ar-H), 7.75 (1H, d, *J* = 8.0 Hz, Ar-H), 7.61-7.59 (1H, m, Ar-H), 7.51-7.47 (1H, m, Ar-H), 7.42-7.38 (2H, m, Ar-H), 7.25-7.17 (2H, m, Ar-H), 6.75 (1H, t, *J* = 7.8 Hz, Ar-H), 6.56 (1H, d, *J* = 8.4 Hz, Ar-H), 5.53 (1H, dd, *J* = 8.0, 16.4 Hz, P-CH), 4.29-3.91 (4H, m, OCH₂), 1.31-1.17 (6H, m, OCH₂CH₃). ¹³C NMR (100 MHz) δ : 169.0 (C₇), 153.3 (C₁), 145.5 (C₁₃), 145.3 (C₁₇), 134.7 (C₆), 134.6 (C₂₀), 134.2 (C₂₂), 133.1 (C₂₁), 132.1 (C₂), 130.5 (C₅), 129.1 (C₁₈), 127.8 (C₁₁), 126.2 (C₁₉), 125.2 (C₉), 122.6 (C₃), 121.1 (C₄), 117.0 (C₈), 116.2 (C₁₀), 112.1 (C₁₂), 64.0 (C₁₅, d, *J* = 6.7 Hz, OCH₂), 63.4 (C₁₅, d, *J* = 7.1 Hz, OCH₂), 52.0 (C₁₄, d, *J* = 154 Hz, P-C), 16.6 (C₁₆, d, *J* = 5.4 Hz, OCH₂CH₃), 16.3 (C₁₆, d, *J* = 5.4 Hz, O-CH₂CH₃). ³¹P NMR (161 MHz) δ : 19.8. EI-MS *m/z*: 521 (M)⁺, 523 (M+2)⁺, 525 (M+4)⁺. Calcd. for C₂₄H₂₃Cl₂N₂O₃PS: C, 55.29; H, 4.45; N, 5.37; Found: C, 55.20; H, 4.34; N, 5.29.

The same procedure was employed for the synthesis of **10-20**.

Ethyl [2-(benzo[d]thiazol-2-yl)phenylamino](2,4-dichlorophenyl)methyl(phenyl)-

phosphinate (15) was obtained as white solid, m. p.: 116-118°C. IR (ν_{\max} , cm^{-1}): 3210 (NH), 1217 (P=O), 1024 (P-O-C). ^1H NMR (500 MHz) δ : 10.33 (1H, s, NH), 8.21 (1H, d, $J = 8.0$ Hz, Ar-H), 8.08 (1H, d, $J = 8.0$ Hz, Ar-H), 7.83-7.35 (6H, m, Ar-H), 7.33-7.06 (6H, m, Ar-H), 6.64-6.57 (1H, m, Ar-H), 6.43 (1H, d, $J = 8.5$ Hz, Ar-H), 5.44 (1H, dd, $J = 7.5, 9.5$ Hz, PCH), 4.22-3.81 (2H, m, OCH₂), 1.30-1.08 (3H, m, OCH₂CH₃). ^{13}C NMR (125 MHz) δ : 168.7 (C₇), 153.4 (C₁), 145.5 (C₁₃), 137.4 (C₂₃), 134.8 (C₂₀), 134.1 (C₂₆), 133.1 (C₆), 132.7 (C₂₈), 132.5 (C_{18, 22}), 132.2 (C₂₄), 131.9 (C₂₅), 130.5 (C₂₇), 130.4 (C₁₇), 128.5 (C_{19, 21}), 127.8 (C₁₁), 126.3 (C₂), 125.1 (C₉), 122.9 (C₄), 122.6 (C₃), 121.5 (C₅), 116.8 (C₈), 116.3 (C₁₀), 112.1 (C₁₂), 62.4 (C_{15, d}, $J = 6.8$ Hz, P-O-CH₂), 54.7 (C₁₄, d, $J = 134.0$ Hz, P-C), 16.6 (C₁₆, d, $J = 5.7$ Hz, P-O-CH₂CH₃). ^{31}P NMR (202 MHz) δ : 35.7. EI-MS m/z : 553 (M)⁺, 555 (M+2)⁺, 557 (M+4)⁺. Calcd. for C₂₈H₂₃Cl₂N₂O₃PS: C, 60.77; H, 4.19; N, 5.06; Found: C, 60.70; H, 4.12; N, 4.97.

ACKNOWLEDGEMENTS

The author, SK. Thaslim Basha expresses thanks to UGC for awarding SRF.

REFERENCES

1. (a) de la Hoz, A.; Draz Ortiz, A.; Moreno, A. *Chem. Soc. Rev.***2005**, *34*, 164-178; (b) Hosseini Sarvari, M.; Sharghi, H. *J. Org. Chem.***2006**, *71*, 6652-6654; (c) Syamala, M. *Org. Prep. Proced. Int.***2009**, *41*, 1-68.
2. Tanaka, K.; Toda, F. *Chem. Rev.***2000**, *100*, 1025-1074.
3. (a) Yamazaki, K.; Kaneko, Y.; Suwa, K.; Ebara, S.; Nakazawa, K.; Yasuno, K. *Bioorg. Med. Chem.***2005**, *13*, 2509-2522; (b) Yalcin, I.; Oren, I.; Sener, E.; Akin, A.; Ucarturk, N. *Eur. J. Med. Chem.***1992**, *27*, 401-406.
4. Palmer, F. J.; Trigg, R. B.; Warrington, J. V. *J. Med. Chem.***1971**, *14*, 248-251.
5. Burger, A.; Sawhey, S. N. *J. Med. Chem.***1968**, *11*, 270-273.
6. Lednicer, D. *Strategies for Organic Drugs Synthesis and Design*, Wiley & Sons, New York, 1998.
7. Sharma, R. N.; Xavier, F. P.; Vasu, K. K.; Chaturvedi, S. C.; Pancholi, S. S. *J. Enzyme Inhib. Med. Chem.***2009**, *24*, 890-897.
8. Diaz, H. M.; Molina, R. V.; Andrade, R. O.; Coutino, D. D.; Franco, L. M.; Webster, S. P.; Binnie, M.; Soto, S. E.; Barajas, M. I.; Rivera, I. L.; Vazquez, G. N. *Bioorg. Med. Chem. Lett.***2008**, *18*, 2871-2877.
9. Jayachandran, E.; Bhatia, K.; Naragud, L. V. G.; Roy, A. *Indian Drugs***2003**, *40*, 408-411.
10. Chugunova, E.; Boga, C.; Sazykin, I.; Cino, S.; Micheletti, G.; Mazzanti, A.; Sazykina, M.; Burilov, A.; Khmelevtsova, L.; Kostina, N. *Eur. J. Med. Chem.***2015**, *93*, 349-359.

11. (a) Karali, N.; Güzel, O.; Ozsoy, N.; Ozbey, S.; Salman, A. *Eur. J. Med. Chem.***2010**, 45, 1068-1077. (b) Cressier, D.; Prouillac, C.; Hernandez, P.; Amourette, C.; Diserbo, M.; Lion, C.; Rima, G. *Bioorg. Med. Chem.***2009**, 17, 5275-5284.
12. (a) Weekes, A. A.; Westwell, A. D. *Curr. Med. Chem.***2009**, 16, 2430-2440; (b) Kini, S.; Swain, S. P.; Gandhi, A. M. *Indian J. Pharm. Sci.***2007**, 69, 46-50.
13. Engels, H.; Weidenhaupt, H.; Pieroth, M.; Hofmann, W.; Menting, K.; Mergenhagen, T.; Schmoll, R.; Uhrland, S. "Rubber, 4. Chemicals and Additives" in *Ullmann's Encyclopedia of Industrial Chemistry* Wiley-VCH, Weinheim 2004.
14. Hrobarik, P.; Sigmundova, I.; Zahradnik, P.; Kasak, P.; Arion, V.; Franz, E.; Clays, K. J. *Phys. Chem. C.***2010**, 114, 22289-22302.
15. Phillips, M. A.; Fletterick, R.; Rutter, W. J. *J. Biol. Chem.***1990**, 265, 20692-20698.
16. Chen, T.; Shen, P.; Li, Y.; He, H. *J. Fluorine Chem.***2006**, 127, 291-295.
17. Bhupendra Reddy, C.; Suresh Kumar, K.; Anil Kumar, M.; Veera Narayana Reddy, M.; Satheesh Krishna, B.; Naveen, M.; Arunasree, M. K.; Suresh Reddy, C.; Naga Raju, C.; Devendranath Reddy, C. *Eur. J. Med. Chem.***2012**, 47, 553-559.
18. Liu, W.; Rogers, C. J.; Fisher, A. J.; Toney, M. D. *Biochem.***2002**, 41, 12320-12328.
19. Hirschmann, R.; Smith, A. B.; Taylor, C. M.; Benkovic, P. A.; Taylor, S. D.; Yager, K. M.; Sprengler, P. A.; Venkovic, S. J. *Science***1994**, 265, 234-237.
20. Pan, W.; Ansiaux, C.; Vincent, S. P. *Tetrahedron Lett.***2007**, 48, 4353-4356.
21. Makhaeva, G. F.; Malygin, V. V.; Aksinenko, A. Y.; Sokolov, V. B.; Strakhova, N. N.; Rasdolsky, A. N.; Richardson, R. J.; Martynov, I. V. *Dokl. Biochem. Biophys.***2005**, 400, 92-95.

22. Atherton, F. R.; Hassall, C. H.; Lambert, R. W. *J. Med. Chem.* **1986**, 29, 29-40.
23. Rasheed, S.; Venkataramana, K.; Chandrasekhar, K.; Fareeda, G.; Naga Raju C. *Arch. Pharm. Chem. Life Sci.* **2012**, 345, 294-301.
24. Subba Rao, D.; Srinivasulu, D.; Rajasekhar, D.; Naga Raju, C. *Chin. Chem. Lett.* **2013**, 24, 759-763.
25. (a) Kafarski, P.; Gorny vel Gorniak, M.; Andrasiak, I. *Curr. Green. Chem* **2015**, 2, 218-222.
(b) Chandrasekhar, S.; Narsihmulu, Ch.; Sultana, S. S.; Saritha, B.; Prakash, S. J. *Synlett* **2003**, 505-506.
26. Keglevich, G.; Szkrenyi, A. *Lett. Org. Chem.* **2008**, 5, 616-622.
27. Bálint, E.; Takács, J.; Drahos, L.; Juranovič, A.; Kočevár, M.; Keglevich, G. *Heteroatom Chem.* **2013**, 24, 221-225.
28. Azarifar, D.; Maleki, B.; Setayeshnazar, A. *Phosphorus Sulfur Silicon Relat. Elem.* **2009**, 184, 2097-2102.
29. (a) Radha Rani, C.; Bhatnagar, I.; Gangireddy, C. S. R.; Syama, S. C.; Suresh Reddy, C. *Arch. Pharm. Chem. Life Sci.* **2013**, 346, 667-676; (b) Sobhani, S.; Safaei, E.; Asadi, M.; Jalili, F. *J. Organomet. Chem.* **2008**, 693, 3313-3317.
30. Barry, A. L. *The Antimicrobial Susceptibility Test: Principle and Practices*, eds Illus lea and Febiger, Philadelphia, PA USA **1976**, pp. 180.
31. Sarker, S. D.; Nahar, L.; Kumarasamy, Y. *Methods* **2007**, 42, 321-324.
32. (a) Bauer, A. W.; Kirby, M. M.; Sherris, J. C. *Am. J. Clin. Pathol.* **1966**, 45, 493-496; (b) National Committee for Clinical Laboratory Standards, *Methods for Dilution, Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*, Approved Standard M7-A5, 5th ed.,

NCCLS, Wayne, PA, 2000, p. 30.

33. (a) Burits, M.; Bucar, F. *Phytother Res.* **2000**, 14, 323-328; (b) Cuendet, M.; Hostettmann, K.;

Otterat, O. P. *Helv. Chim. Acta.* **1997**, 80, 1144-1152.

34. Ruch, R. J.; Cheng, S. J.; Klaunig, J. E. *Carcinogenesis* **1989**, 10, 1003-1008.




Figure 1. Effect of microwave oven power (Watt) on the yield of the compound **9**.







Figure 2. Half inhibitor concentration values of the title compounds 9-20.



Scheme 1. Synthesis of 2-(2-aminophenyl)benzothiazole (5).



Scheme 2. Model reaction for the synthesis of diethyl(2(benzo[*d*]thiazol-2-yl)phenylamino)(2,4-dichlorophenyl)methylphosphonate (**9**).



Compd.	6a	6b	6c	6d	6e	6f
Aryl/Hetero						

Scheme 3. Schematic representation of the synthesized compounds of α -aminophosphonates (**9-20**).